President Trump signed an executive order to fast-track the study of using psychedelic drugs to treat Americans – especially veterans – living with depression, PTSD and other conditions.

President Donald Trump signed an executive order allowing the use of some psychedelic drugs to treat post-traumatic stress disorder. Flanked by Health and Human Services Secretary Robert F. Kennedy Jr.

The White House is preparing an executive order to expand federal research into ibogaine, a psychedelic drug used in some countries to treat PTSD, CBS News reported April 16.  The Trump administration plans to keep ibogaine classified as a Schedule I substance and does not intend to approve it for medical use at this time.

President Trump's executive order on investigational psychedelic therapies for veterans may mark a turning point in mental health treatment.

“Our study provides a comprehensive and independent assessment of the benefits and risks of cannabis medicines, which may support the TGA and clinicians to make evidence-based decisions, helping to ensure patients receive effective treatments while minimizing harm from ineffective or unsafe cannabis products,” Dr. Wilson said.

A man who struck and killed a jogger last year in Nebraska is suing the victim’s estate for PTSD-related damages.

Trump has announced a drug policy reform to ease restrictions on psychedelics to support veterans' mental health treatment.